How much does a disrupted mitochondrial network influence neuronal dysfunction? by Chrzanowska-Lightowlers ZM & Lightowlers RN
News & Views
How much does a disrupted
mitochondrial network influence
neuronal dysfunction?
Zofia MA Chrzanowska-Lightowlers1 & Robert N Lightowlers2
Mitochondria are organelles that are
present in all nucleated cells in the body.
They have manifold functions but famously
generate ATP efficiently through the
process of oxidative phosphorylation. This
ensures all tissues have an adequate
energy supply and underlines the need for
a fully functional mitochondrial network.
Since mitochondrial biogenesis and main-
tenance require components from two
genetic sources, mitochondrial diseases
can result from mutations in either the
nuclear or the mitochondrial genome
(mtDNA). Enigmatically, mitochondrial
disease can affect individuals at any age
and in any tissue (Lightowlers et al, 2015).
For a subset of mutations, the genotype
can be ascribed to a clinical phenotype and
a number of mutations are associated with
remarkable tissue selectivity (Boczonadi
et al, 2018). However, the gene expression
pathways governing this tissue-specific
presentation are far from clear. In this
issue of EMBO Molecular Medicine,
Sprenger et al (2018) use mouse models to
investigate the consequences of deleting
a mitochondrial protease, YME1L, in
neuronal/glial precursors. The loss causes
multiple defects at both cell and tissue
level, including a marked fragmentation of
the mitochondrial network. Tandem deple-
tion of a second mitochondrial protease,
Oma1, successfully restored the mitochon-
drial connectivity, but did not rescue the
ocular defects and caused an earlier onset
of neurological dysfunction. Thus, in
addition to other findings, the authors
conclude that a fragmented mitochondrial
network contributes less to the disease
phenotype than the disruption of mito-
chondrial proteostasis.
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M itochondria perform a number ofkey functions within the cell butare probably most frequently asso-
ciated with the production of ATP. To
assemble much of the chain of enzyme
complexes that perform oxidative phospho-
rylation (OXPHOS) requires coordinated
expression and assembly of gene products
from both the nuclear and the mitochondrial
genome. The catalogue of diseases associ-
ated with mitochondrial dysfunction contin-
ues to increase, and in many cases, the
ubiquity of exome or whole genome
sequencing has enabled the identification of
the genetic mutations responsible for these
pathogenic defects (Taylor et al, 2014). At
present, there is no cure for these diseases
and treatment, where possible, is currently
limited to ameliorating the symptoms of the
common presentations, rather than address-
ing the cause. Work on preventing the trans-
mission of mtDNA mutations is ongoing
(Herbert & Turnbull, 2018), but this will not
address the problems caused by nuclear-
encoded defects. To develop potential thera-
pies for these conditions, which can be
varied in presentation, we need to increase
our knowledge of the specific consequences
of the mutations in a whole organism.
Amongst the different tissue phenotypes,
neuronal dysfunction or degradation are
common features of mitochondrial disease.
However, determining the molecular patho-
genesis is challenging. The use of mouse
models to address such questions can be
very informative. This approach has been
adopted by the Langer laboratory to investi-
gate the molecular consequences of muta-
tions in the mitochondrial i-AAA protease,
YME1L. The latter is an enzyme that is
responsible for the homeostasis both of
mitochondrial proteins and phospholipids. It
does so mostly by removing proteins that
are damaged or have not been correctly
assembled into functional complexes and by
degrading short-lived lipid transfer proteins
(Coenen et al, 2005; Stiburek et al, 2012).
Essentially, this prevents the organelle
becoming clogged up with dysfunctional
debris that would impede mitochondrial
function. Additionally, one of the YME1L
targets is a dynamin-like GTPase, OPA1,
which is crucial for maintenance of mito-
chondrial dynamics through its involvement
in mitochondrial fusion and cristae forma-
tion. Pathogenic mutations in YME1L have
been identified, and patients harbouring
homozygous recessive mutations frequently
present with a neuromuscular disorder
including movement disturbances and optic
atrophy (Hartmann et al, 2016). At a cellular
level, the mitochondrial network becomes
1 Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Medical School, Newcastle University, Newcastle upon Tyne, UK.
E-mail: Zofia.Chrzanowska-Lightowlers@ncl.ac.uk
2 Wellcome Centre for Mitochondrial Research, Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle upon Tyne, UK
DOI 10.15252/emmm.201809899
ª 2018 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine e9899 | 2018 1 of 3
highly fragmented in the affected tissues.
This is explained by the stress-activated
cleavage of the long isoform of Opa1 (L-
Opa1) by a different protease, Oma1, in the
Yme1l knockout mouse model. This longer
isoform is essential for promoting the fusion
of the inner mitochondrial membrane (Ban
et al, 2017) and its absence results in a loss
of fusion. Interestingly, although fragmented
mitochondrial networks can be associated
with defects in oxidative phosphorylation,
loss of Yme1l in mice caused disrupted mito-
chondrial morphology and neurological
defects independently of any significant defi-
cits in oxidative phosphorylation.
What is the relationship between this
change in mitochondrial morphology, eye
defects and axonal degeneration with age?
Sprenger et al have used two knockout
mouse models to address this question. One
mouse line has been generated in which
Yme1l is specifically knocked out in neuronal
and glial cell precursors. The second line
eliminates both YME1L and the IM pepti-
dase, OMA1, which can cleave OPA1 but is
usually only activated under stress condi-
tions (Zhang et al, 2014). Sprenger et al have
characterised the phenotypes arising from
both the individual or combined neuronal-
specific knockout mice (Fig 1). In humans,
mutations in YME1L cause ocular dysfunc-
tion and movement disturbances. The mouse
model eliminating Yme1l alone displayed a
comparable phenotype with ocular defects
including retinal inflammation, cataracts and
microphthalmia, a developmental condition
where the eyes are abnormally small. This
condition is generally associated with
increased caspase 9-mediated cell death but
in the absence of YME1L there was no appar-
ent stimulation of this pathway, suggesting
a different cause for the microphthalmia.
Investigating the temporal nature of the
neurological impairment identified that the
eye-related defects (microphthalmia, catar-
acts, retinal disorganisation) occurred early
on, whilst the axonal and locomotor degener-
ation only developed later, and were not the
consequence of generalised brain atrophy.
The tandem knockout of both YME1L and
OMA1 restored the dynamic mitochondrial
network, but despite this restoration of L-
OPA1, not only did the combination of eye
defects persist but both the neuroinflamma-
tion and axonal degeneration became more
severe, with an earlier onset. The combina-
tion of models used in these investigations
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Figure 1. A connected mitochondrial network is not sufficient to overcome the physiological defects arising from a loss of YME1L.
(A) YME1L activity in wild-type mice maintains a balance of OPA1 forms to retain a dynamic mitochondrial reticulum. (B) Loss of YME1L from neuronal and glial precursors
results in a fragmented mitochondrial network, eye defects and late onset of neuroinflammation, with degeneration of dorso-lateral tract-specific axons leading to
locomotor impairment. (C) Loss of OMA1 results in stabilisation of L-OPA1 with increased connectivity of mitochondrial tubules, with mild lipid-related symptoms under
control conditions (Quiros et al, 2012). (D) When both of the proteases responsible for processing of OPA1 are knocked out, the reticular nature of the mitochondrial network
is restored but the defects associated with loss of YME1L alone are retained or even exacerbated.
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brings us a little closer to understanding
pathogenic mechanisms and that disruption
of mitochondrial proteostasis alone can be a
driver for disease.
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